Key facts
- Pharmazz’s last known valuation is $588.0M (Jun 2025).
- It has raised $45.8M across 8 recorded rounds; the latest was Early Stage VC ($10.0M) in May 2025.
- Notable investors include Keiretsu Forum, Lung, National Heart, Sun Pharmaceutical Industries, and Blood Institute.
- Pharmazz has filed 12 Form Ds with the SEC since 2018, most recently Jun 2025 ($10.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pharmazz
Funding rounds
8 roundsAbout Pharmazz
Operator of a pharmaceutical company intended to focus on discovering, acquiring, developing, and commercializing therapeutics. The company's products include therapeutics for hypovolemic shock, postoperative pain, cardiac arrest, Alzheimer's disease, ischemic stroke, spinal cord injury, tumour diagnosis, diabetic ketoacidosis, and opioid tolerance, enabling hospitals to avail products for the diagnosis and treatment of clinical conditions that require critical care and hospital settings.
- Sector
- Healthcare
- HQ
- Willowbrook, IL, United States
- Founded
- 2010
- Employees
- 44
- Website
- pharmazz.com/
- Ownership
- Privately Held (backing)
Pharmazz doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharmazz shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharmazz in its N-PORT filings yet. We sweep new filings monthly.